share_log

Have Insiders Sold Silk Road Medical Shares Recently?

Have Insiders Sold Silk Road Medical Shares Recently?

內部人士最近是否出售了絲路醫療股票?
Simply Wall St ·  03/09 08:19

Anyone interested in Silk Road Medical, Inc (NASDAQ:SILK) should probably be aware that the CFO & COO, Lucas Buchanan, recently divested US$170k worth of shares in the company, at an average price of US$17.17 each. On the bright side, that sale was only 6.0% of their holding, so we doubt it's very meaningful, on its own.

任何對絲路醫療公司(納斯達克股票代碼:SILK)感興趣的人都應該知道,首席財務官兼首席運營官盧卡斯·布坎南最近以平均每股17.17美元的價格剝離了該公司價值17萬美元的股份。好的一面是,那次出售僅佔他們持股量的6.0%,因此我們懷疑這本身是否有意義。

The Last 12 Months Of Insider Transactions At Silk Road Medical

絲路醫療過去12個月的內幕交易

Notably, that recent sale by Lucas Buchanan is the biggest insider sale of Silk Road Medical shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$16.40. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

值得注意的是,盧卡斯·布坎南最近的出售是我們在去年看到的最大規模的絲綢之路醫療股票內幕出售。這意味着一位內部人士正在以當前的16.40美元左右的價格出售股票。儘管內幕拋售是負面的,但對我們來說,如果以較低的價格出售股票,則負面影響更大。在這種情況下,大甩賣是在當前價格左右進行的,因此還不錯(但仍然不是積極的)。

Silk Road Medical insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

去年,絲路醫療內部人士沒有購買任何股票。您可以看到下圖所示的去年的內幕交易(公司和個人)。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!

insider-trading-volume
NasdaqGS:SILK Insider Trading Volume March 9th 2024
納斯達克股票代碼:2024年3月9日SILK內幕交易量

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Does Silk Road Medical Boast High Insider Ownership?

絲綢之路醫療是否擁有很高的內部所有權?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Silk Road Medical insiders own about US$13m worth of shares. That equates to 2.1% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。絲路醫療內部人士擁有價值約1300萬美元的股票。這相當於該公司的2.1%。當然,我們在其他地方看到了更高的內部所有權水平,但這些持股足以表明內部人士與其他股東之間的一致性。

So What Does This Data Suggest About Silk Road Medical Insiders?

那麼這些數據對絲綢之路醫學內部人士有什麼啓示呢?

Insiders haven't bought Silk Road Medical stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we found 2 warning signs for Silk Road Medical that deserve your attention before buying any shares.

內部人士在過去三個月中沒有買入絲綢之路醫療的股票,但出現了一些拋售。在過去的一年裏,沒有任何能讓我們感到安慰的購買。內部人士擁有股票,但考慮到銷售歷史,我們仍然相當謹慎。購買前我們會謹慎行事!因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解該公司面臨的風險。在Simply Wall St,我們發現了絲路醫療的兩個警告信號,在購買任何股票之前,值得你注意。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論